Clinical Trials Directory

Trials / Completed

CompletedNCT02846441

Interstage Assessment of Remnant Liver Function in ALPPS

Interstage Assessment of Remnant Liver Function in ALPPS: Can SPECT Hepatobiliary Scintigraphy Provide Any Additional Value in Predicting Risk of Posthepatectomy Liver Failure?

Status
Completed
Phase
Study type
Observational
Enrollment
20 (actual)
Sponsor
Hospital Italiano de Buenos Aires · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Post-hepatectomy liver failure is one of the most feared complications by hepatic surgeons. When size of the future liver remnant (FLR) is regarded to be not sufficient to sustain post-hepatectomy liver function, techniques as preoperative portal vein embolization or two-stage hepatectomy/associating liver partition and portal vein ligation (ALPPS) can be performed. ALPPS induces rapid and extensive hypertrophy by portal vein ligation and in situ liver splitting. To date, feasibility of the second stage of ALPPS has been assessed only on the basis of standardized future liver remnant or future liver remnant on body weight. However, decrease of liver function between stages, measured by means of laboratory parameters, has been demonstrated to be associated with higher 90-day mortality, regardless of FLR volume. In other words, this volumetric increase may not reflect the increase of liver function.

Detailed description

The aim of this study is to determine the predictive value of hepatobiliary scintigraphy with 99mTc-mebrofenin between stages in ALPPS, in assessing risk of postoperative liver failure and liver failure-related mortality after completion of stage 2.

Conditions

Interventions

TypeNameDescription
PROCEDUREhepatobiliary scintigraphy99mTc-mebrofenin hepatobiliary scintigraphy with single photon emission computed tomography (SPECT)

Timeline

Start date
2011-07-01
Primary completion
2016-03-01
Completion
2016-06-01
First posted
2016-07-27
Last updated
2016-07-28

Locations

1 site across 1 country: Argentina

Source: ClinicalTrials.gov record NCT02846441. Inclusion in this directory is not an endorsement.